Regional plus systemic chemotherapy: an effective treatment in recurrent non-small cell lung cancer.

AIMS This study was undertaken to determine the activity and toxicity of regional chemotherapy using an isolated thoracic perfusion (ITP) technique as second-line treatment for patients with advanced and recurrent non-small cell lung cancer (NSCLC). METHODS Eighteen patients with relapsed NSCLC confined to the thoracic region entered the study and received regional chemotherapy using ITP plus low-dose systemic chemotherapy. All 18 patients had been pre-treated with some form of chemotherapy, surgery and/or radiotherapy. The cytostatic regimen had two components: (1) ITP using mitomycin 10 mg/m(2), navelbine 25 mg/m(2)and cisplatin 30 mg/m(2)on day 1; (2) systemic chemotherapy with 5-fluorouracil 250 mg/m(2)and cisplatin 20 mg/m(2)given as a continuous infusion over 24 h on days 1-4. RESULTS All 18 patients were assessable for toxicity, tumour response and survival. There were 10/18 responses (CR 0; PR 10): a response rate of 56%. Side-effects were transient and acceptable. No treatment-related death occurred. Median survival was 21 months and the 1-year survival rate was 75%. CONCLUSIONS Regional chemotherapy using ITP plus low-dose systemic chemotherapy is effective in recurrent advanced NSCLC, with an encouraging survival outcome.

[1]  F. Russo,et al.  Stop-flow in mediastinum and thorax for resistant lymphoma. , 2000, Hepato-gastroenterology.

[2]  C. Camps,et al.  Second-line treatment with gemcitabine and vinorelbine in non-small-cell lung cancer (NSCLC) cisplatin failures: a pilot study. , 2000, Lung cancer.

[3]  A. Rossi,et al.  Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC): a phase II trial. , 1999, Anticancer research.

[4]  G. Scagliotti,et al.  Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  G. Stathopoulos,et al.  Paclitaxel combined with cis-platin as second-line treatment in patients with advanced non-small cell lung cancers refractory to cis-platin. , 1999, Oncology reports.

[6]  J. Rigas,et al.  The use of docetaxel (Taxotere) in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. , 1999, Seminars in oncology.

[7]  E. van Marck,et al.  Isolated Lung Perfusion with Melphalan Prolongs Survival in a Rat Model of Metastatic Pulmonary Adenocarcinoma , 1999, European Surgical Research.

[8]  M. Socinski,et al.  Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: report of a phase II trial. , 1999, Cancer investigation.

[9]  A. Perel,et al.  Hemodynamic changes during a new procedure for regional chemotherapy involving occlusion of the thoracic aorta and inferior vena cava. , 1998, Journal of clinical anesthesia.

[10]  H. Machida,et al.  [An experimental study of local chemotherapy for metastatic lung tumor--isolated lung perfusion and pulmonary artery infusion]. , 1998, The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi.

[11]  M. Burt,et al.  Cytostatic lung perfusion by use of an endovascular blood flow occlusion technique. , 1998, The Annals of thoracic surgery.

[12]  C. Belani.  Single agents in the second-line treatment of non-small cell lung cancer. , 1998, Seminars in oncology.

[13]  K. Dickersin,et al.  Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma , 1998, Cancer.

[14]  F. Fossella,et al.  Management strategies for recurrent non-small cell lung cancer. , 1997, Seminars in oncology.

[15]  M. Dimopoulos,et al.  Second-line treatment of advanced non-small cell lung cancer with paclitaxel and gemcitabine: a preliminary report on an active regimen. , 1997, Seminars in oncology.

[16]  M. Burt,et al.  Isolated lung perfusion with doxorubicin prolongs survival in a rodent model of pulmonary metastases. , 1997, The Annals of thoracic surgery.

[17]  M. Burt,et al.  Isolated lung perfusion with melphalan for the treatment of metastatic pulmonary sarcoma. , 1996, The Journal of thoracic and cardiovascular surgery.

[18]  M. Burt,et al.  Isolated lung perfusion with doxorubicin reduces cardiac and host toxicities associated with systemic administration. , 1996, The Annals of thoracic surgery.

[19]  C. Dawson,et al.  Lung perfusion with chemotherapy in patients with unresectable metastatic sarcoma to the lung or diffuse bronchioloalveolar carcinoma. , 1995, The Journal of thoracic and cardiovascular surgery.

[20]  M. Burt,et al.  Isolated lung perfusion with FUDR is an effective treatment for colorectal adenocarcinoma lung metastases in rats. , 1995, The Annals of thoracic surgery.

[21]  M. Cullen.  The MIC regimen in non-small cell lung cancer , 1993 .

[22]  S. Kaasa,et al.  Polychemotherapy in advanced non small cell lung cancer: a meta-analysis , 1993, The Lancet.

[23]  I. Smith,et al.  Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer. , 1989, British Journal of Cancer.